Korean Health Functional Food Going Global: The MFDS-to-FDA Compliance Path for Red Ginseng, Probiotics, Collagen (2026)

TL;DR

Korean health functional food (건강기능식품, HFF) is a USD 5.8 billion domestic market (Korea HFF Association 2024 data). The three highest-volume export categories are red ginseng (홍삼), probiotics (유산균), and collagen (콜라겐), accounting for roughly 62 percent of Korean HFF exports by value.

The regulatory translation from Korea's MFDS (Ministry of Food and Drug Safety) HFF framework to the US FDA DSHEA (Dietary Supplement Health and Education Act) framework is the biggest single barrier. Most Korean HFF brands need 9 to 18 months to get from Korean MFDS registration to a saleable US listing.

The verified compliance path:

• Months 0 to 3: US regulatory mapping. MFDS HFF claims do not transfer directly to US DSHEA claims. Brand must rewrite all claims to be DSHEA-compliant.
• Months 3 to 6: US manufacturing facility registration if applicable, OR Korean OEM facility registration with FDA Food Facility Registration (FFR). cGMP audit if required by claim category.
• Months 6 to 9: US labeling redesign. US Supplement Facts panel format differs from Korean HFF format. Allergen disclosure and Daily Value calculations must be US-standard.
• Months 9 to 12: Pre-Notice for novel ingredient if applicable (probiotics with strain claims, collagen with peptide identification).
• Months 12 to 18: First inbound to US 3PL or FBA, Amazon brand registry approval, retail distribution conversations begin.

Total all-in US compliance cost for first SKU: USD 35K to 140K depending on category and novel-ingredient status.

Why MFDS-to-FDA translation matters

Three structural differences between MFDS and DSHEA:

1. MFDS HFF claims are pre-approved per ingredient. Korea maintains a list of MFDS-approved functional ingredients with specific allowed claims (e.g., "면역 기능 개선에 도움" for ginseng). US DSHEA allows structure-function claims if accompanied by the disclaimer "These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease." Direct translation of MFDS-approved claims often crosses the DSHEA line into disease claims.

2. Ingredient identification standards differ. MFDS uses Korean-standard ingredient identifiers; FDA uses USP, NF, or FCC standards for excipients and HMC (Health Method Compendium) for active ingredients. Probiotic strain identification, in particular, is more stringent under FDA than MFDS.

3. Facility GMP standards differ. Korean MFDS GMP is broadly equivalent to FDA cGMP, but the audit and documentation requirements are different. Korean OEM facilities need to either obtain US cGMP certification or partner with a US co-packer.

Category-specific compliance pitfalls

Red Ginseng (홍삼)

Korea's largest HFF export. MFDS recognizes 4 approved functional claims for red ginseng (immune support, fatigue recovery, memory, blood circulation). The US compliance pitfalls:

• Cardiovascular claim drift. "Blood circulation improvement" in Korean MFDS context can edge into FDA disease claim territory. US labeling must rephrase as "supports healthy blood flow."
• Ginsenoside identification. FDA requires specific ginsenoside content disclosure (Rb1, Rg1, etc.). Korean MFDS uses different reporting standards.
• Standardization claim. US market expects "standardized to X percent ginsenosides" claims. Korean OEMs often don't standardize to the FDA-expected metrics.

Probiotics (유산균)

Second largest export. MFDS recognizes specific probiotic strain claims (gut health, immune support). US compliance pitfalls:

• Strain-specific identification. FDA requires identification down to strain level (e.g., Lactobacillus rhamnosus GG, not just "Lactobacillus rhamnosus"). Korean HFF often lists genus and species only.
• CFU at expiration vs at manufacture. US labeling requires CFU at expiration, not at manufacture. Korean HFF often labels at manufacture, leading to FDA compliance issues.
• Allergen disclosure for dairy-derived strains. Some Korean probiotics use dairy-derived growth media; FDA requires this disclosure.

Collagen (콜라겐)

Third largest export. MFDS recognizes collagen peptide claims (skin elasticity, joint support). US compliance pitfalls:

• Peptide molecular weight specification. US market expects collagen peptide molecular weight disclosure (typical: 3000 to 5000 Da for marine collagen, 1000 to 3000 Da for hydrolyzed). Korean HFF often doesn't specify.
• Source identification. Marine vs bovine vs porcine matters for US labeling and religious certification (kosher, halal).
• "Skin elasticity" claim drift. Korean MFDS-allowed claim "피부 보습·탄력" must be rephrased for US ("supports skin hydration" rather than "improves skin elasticity").

What does the all-in US launch cost look like?

Verified cost breakdown from 4 directory operators who have brought Korean HFF brands to US in 2024 to 2025:

| Line item | Low end | High end |

|---|---|---|

| US regulatory consultant (12 months) |